Inhibrx (INBX) News Today $13.83 -0.50 (-3.49%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Inhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Third Quarter 2024 Financial ResultsNovember 15 at 10:58 PM | finanznachrichten.deStocks Close Lower on Hawkish PowellNovember 14 at 8:28 PM | msn.comInhibrx Biosciences Inc (INBX)November 14 at 8:28 PM | investing.comInhibrx Biosciences Reports Third Quarter 2024 Financial ResultsNovember 14 at 4:24 PM | prnewswire.comInhibrx Biosciences: Reincorporated And Trying To Find A Niche With Unique PlatformNovember 5, 2024 | seekingalpha.comInhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and InnovationNovember 4, 2024 | prnewswire.comInhibrx Biosciences (NASDAQ:INBX) Stock Quotes, Forecast and News SummaryOctober 18, 2024 | benzinga.comInhibrx, Inc. (NASDAQ:INBX) Short Interest UpdateInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 742,500 shares, an increase of 9.6% from the September 15th total of 677,700 shares. Based on an average trading volume of 106,900 shares, the short-interest ratio is presently 6.9 days. Approximately 7.4% of the shares of the company are short sold.October 16, 2024 | marketbeat.comInhibrx CEO buys shares worth over $629kSeptember 19, 2024 | investing.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 13,037 SharesSeptember 17, 2024 | insidertrades.comDirector Kristiina Vuori Purchases Shares of Inhibrx Biosciences Inc (INBX)September 13, 2024 | finance.yahoo.comInhibrx, Inc. (NASDAQ:INBX) CEO Purchases $144,495.00 in StockSeptember 11, 2024 | insidertrades.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Purchases 9,500 SharesInhibrx, Inc. (NASDAQ:INBX - Get Free Report) CEO Mark Lappe acquired 9,500 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were bought at an average price of $15.21 per share, for a total transaction of $144,495.00. Following the transaction, the chief executive officer now owns 657,048 shares of the company's stock, valued at $9,993,700.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.September 10, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) CEO Mark Lappe Acquires 10,000 SharesSeptember 4, 2024 | insidertrades.comInsider Buying: Inhibrx, Inc. (NASDAQ:INBX) CEO Buys 10,000 Shares of StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) CEO Mark Lappe acquired 10,000 shares of the company's stock in a transaction on Thursday, August 29th. The stock was acquired at an average cost of $14.03 per share, with a total value of $140,300.00. Following the completion of the purchase, the chief executive officer now directly owns 135,000 shares in the company, valued at $1,894,050. The purchase was disclosed in a filing with the SEC, which is available at this link.September 3, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Sees Large Growth in Short InterestInhibrx, Inc. (NASDAQ:INBX - Get Free Report) saw a large increase in short interest during the month of August. As of August 15th, there was short interest totalling 752,900 shares, an increase of 6.0% from the July 31st total of 710,400 shares. Approximately 7.3% of the company's shares are short sold. Based on an average trading volume of 203,400 shares, the short-interest ratio is currently 3.7 days.September 2, 2024 | marketbeat.comInhibrx gains after insider purchases from CEOAugust 23, 2024 | msn.comINBX Stock Earnings: Inhibrx Beats EPS for Q1 2024August 22, 2024 | investorplace.comINBX Inhibrx Biosciences, Inc.August 17, 2024 | seekingalpha.comInhibrx (NASDAQ:INBX) Posts Quarterly Earnings Results, Beats Estimates By $129.08 EPSInhibrx (NASDAQ:INBX - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported $125.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.60) by $129.08. The business had revenue of $0.10 million for the quarter.August 14, 2024 | marketbeat.comInhibrx Biosciences, Inc.: Inhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 14, 2024 | finanznachrichten.deJMP Securities Remains a Hold on Inhibrx Biosciences Inc (INBX)August 14, 2024 | markets.businessinsider.comInhibrx Biosciences Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 13, 2024 | prnewswire.comJMP Securities Initiates Coverage of Inhibrx Biosciences (INBX) with Market Perform RecommendationJuly 24, 2024 | msn.comJMP Securities Begins Coverage on Inhibrx (NASDAQ:INBX)JMP Securities initiated coverage on shares of Inhibrx in a report on Tuesday. They set a "market perform" rating for the company.July 23, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. trimmed its position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 56.3% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 190,389 shares of the compaJuly 22, 2024 | marketbeat.comInhibrx (NASDAQ:INBX) Shares Down 2.4% Inhibrx (NASDAQ:INBX) Trading Down 2.4%June 12, 2024 | marketbeat.comInhibrx (NASDAQ:INBX) Shares Gap Up on Insider Buying ActivityInhibrx (NASDAQ:INBX) Shares Gap Up Following Insider Buying ActivityJune 10, 2024 | marketbeat.comPlatinum Investment Management Ltd. Sells 61,273 Shares of Inhibrx, Inc. (NASDAQ:INBX)Platinum Investment Management Ltd. cut its position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 26.8% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 167,763 shares of the company's stockJune 9, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Director Purchases $996,748.68 in StockJune 8, 2024 | insidertrades.comInhibrx, Inc. (NASDAQ:INBX) Director Buys $996,748.68 in StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) Director Jon Faiz Kayyem acquired 57,549 shares of the business's stock in a transaction dated Wednesday, June 5th. The stock was acquired at an average cost of $17.32 per share, with a total value of $996,748.68. Following the completion of the transaction, the director now owns 1,150,410 shares of the company's stock, valued at $19,925,101.20. The transaction was disclosed in a filing with the SEC, which is available at this link.June 7, 2024 | marketbeat.comInhibrx: Continued Advancement Even After INBRX-101 Sale To SanofiJune 7, 2024 | seekingalpha.comInhibrx (NASDAQ:INBX) Trading Up 2%Inhibrx (NASDAQ:INBX) Shares Up 2%June 7, 2024 | marketbeat.comCapital Research Global Investors Sells 509,361 Shares of Inhibrx, Inc. (NASDAQ:INBX)Capital Research Global Investors trimmed its position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 41.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 712,360 shares of the company's stock after selling 509,361 shares during the qJune 7, 2024 | marketbeat.comInhibrx (NASDAQ:INBX) Sees Unusually-High Trading VolumeInhibrx (NASDAQ:INBX) Sees Large Volume IncreaseJune 5, 2024 | marketbeat.comTop 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)June 5, 2024 | benzinga.comInhibrx (NASDAQ:INBX) Sets New 12-Month High at $16.83Inhibrx (NASDAQ:INBX) Sets New 1-Year High at $16.83June 3, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Insider Brendan P. Eckelman Sells 300,000 SharesMay 31, 2024 | insidertrades.comInsider Selling: Inhibrx, Inc. (NASDAQ:INBX) Insider Sells 300,000 Shares of StockInhibrx, Inc. (NASDAQ:INBX - Get Free Report) insider Brendan P. Eckelman sold 300,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.30, for a total value of $10,290,000.00. Following the transaction, the insider now owns 1,735,553 shares in the company, valued at approximately $59,529,467.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.May 30, 2024 | marketbeat.comInhibrx, Inc.: Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 25, 2024 | finanznachrichten.deInhibrx Inc. Stockholders Approve Sale of INBRX-101 to SanofiMay 24, 2024 | prnewswire.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffMay 10, 2024 | finance.yahoo.comInhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-OffMay 10, 2024 | prnewswire.comINHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBXMay 9, 2024 | businesswire.comInhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated MergerMay 8, 2024 | prnewswire.comRussell Investments Group Ltd. Decreases Stock Position in Inhibrx, Inc. (NASDAQ:INBX)Russell Investments Group Ltd. lowered its position in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 5.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 435,450 shares of the company's stock after selling 23,606 shareMay 4, 2024 | marketbeat.comAs more rare disease therapies launch, their prices are risingApril 16, 2024 | msn.comInhibrx, Inc. (NASDAQ:INBX) Short Interest Down 17.9% in MarchInhibrx, Inc. (NASDAQ:INBX - Get Free Report) saw a large decrease in short interest in March. As of March 15th, there was short interest totalling 1,600,000 shares, a decrease of 17.9% from the February 29th total of 1,950,000 shares. Based on an average daily trading volume, of 757,800 shares, the days-to-cover ratio is presently 2.1 days. Currently, 4.5% of the shares of the company are sold short.March 30, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Shares Acquired by Wellington Management Group LLPWellington Management Group LLP grew its holdings in Inhibrx, Inc. (NASDAQ:INBX - Free Report) by 24.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 174,899 shares of the company's stock after acquiring an additionalMarch 28, 2024 | marketbeat.comInhibrx, Inc. (NASDAQ:INBX) Sees Significant Drop in Short InterestInhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a significant decrease in short interest during the month of February. As of February 29th, there was short interest totalling 1,950,000 shares, a decrease of 7.1% from the February 14th total of 2,100,000 shares. Based on an average daily volume of 747,100 shares, the days-to-cover ratio is presently 2.6 days. Currently, 5.5% of the shares of the company are sold short.March 18, 2024 | marketbeat.com Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Back, but DC’s Coming for Your Money! (Ad)Trump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy with a heavy hand—building up infrastructure, slapping tariffs on imports, and going all-in on U.S. jobs. But here's the kicker: while Trump's focused on making America stronger, the Washington elite is ready to fight back… Get ahead of the game with 3 proven strategies to protect your retirement from Washington's next mov INBX Media Mentions By Week INBX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INBX News Sentiment▼0.050.55▲Average Medical News Sentiment INBX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INBX Articles This Week▼61▲INBX Articles Average Week Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Pieris Pharmaceuticals News Prothena News Cullinan Therapeutics News 89bio News Rapport Therapeutics News Autolus Therapeutics News Cronos Group News Erasca News Tyra Biosciences News Pliant Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INBX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INBX Stock Alerts